🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
39.24
+0.31 (0.80%)
Nov 20, 2026, 2:38 PM EST - Market open

CRISPR Therapeutics AG Stock Forecast

Stock Price Forecast

According to 23 analysts polled by S&P Global, CRISPR Therapeutics AG stock has a consensus rating of "Buy" and an average price target of $85.42. The average 1-year stock price forecast is 117.69% higher than the current stock price, while the lowest is $44 (+12.13%) and the highest is $291 (+641.59%).

Price Target: $85.42 (+117.69%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$44$85.42$80$291
Change+12.13%+117.69%+103.87%+641.59%

Analyst Ratings

The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy1098899
Buy545544
Hold109991010
Sell000000
Strong Sell000000
Total252222222323

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$80
BuyReiterates$80+103.87%Nov 16, 2026
UBS
UBS
Hold
Maintains
$52
HoldMaintains$52+32.52%Nov 10, 2026
Needham
Needham
Buy
Maintains
$82
BuyMaintains$82+108.97%Nov 9, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
$67
BuyMaintains$67+70.74%Nov 9, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$110
BuyReiterates$110+180.33%Nov 9, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
35.49M
from 3.51M
Increased by 910.97%
Revenue Next Year
134.07M
from 35.49M
Increased by 277.83%
EPS This Year
-4.53
from -6.47
EPS Next Year
-3.67
from -4.53
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
914.96M1.20M371.21M37.31M3.51M35.49M
Revenue Growth
127,154.94%-99.87%30,885.48%-89.95%-90.59%910.97%
Operating Income
373.53M-673.16M-222.54M-466.57M-568.32M-508.72M
Net Income
377.66M-650.18M-153.61M-366.25M-581.60M-436.74M
EPS
-----6.47-4.53
Free Cash Flow
-----345.93M-417.89M
No. Analysts
-----19
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High80.9M
Avg35.5M
Low12.3M

Revenue Growth

Revenue Growth202620272028
High
2,204.4%
Avg
911.0%
Low
251.3%

EPS Forecast

EPS202620272028
High-4.12
Avg-4.53
Low-4.99

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-